WASHINGTON and REDWOOD CITY, Calif., April 03, 2017 (GLOBE NEWSWIRE) — OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, presented data from multiple preclinical studies detailing the mechanism and anti-tumor activity of anti-TIGIT alone and in combination with checkpoint inhibitors at the AACR ...
The post OncoMed Presents Preclinical Data for Anti-TIGIT Program at the American Association for Cancer Research Annual Meeting 2017 appeared first on ForexTV.
April 03, 2017 at 10:08PM
http://ift.tt/2otYGJT
from Nasdaq NewsFeed
http://ift.tt/2otYGJT
No comments:
Post a Comment